The global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
Co-development partnering allow the parties to securitize value and reduce risk, but keep a part of the potential upside should the product reach the market. Event if the licensor does not commercialize the project they can either sell those rights to the licensee partner or another partner for an amount higher than would have been achieved at an earlier stage licensing deal.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LPI (publisher)' newest research report, the 鈥淐o-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Industry Forecast鈥� looks at past sales and reviews total world Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics sales in 2024, providing a comprehensive analysis by region and market sector of projected Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics sales for 2025 through 2031. With Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics industry.
This Insight Report provides a comprehensive analysis of the global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics.
This report presents a comprehensive overview, market shares, and growth opportunities of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics market by product type, application, key players and key regions and countries.
Segmentation by Type:
Asset purchase
Assignment
Co-development
Co-market
Co-promotion
Collaborative R&D
Contract service
CRADA
Cross-licensing
Others
Segmentation by Application:
Industry sector
Therapy areas
Technology type
Deal components
Financial terms
Stage of development
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
1ST Biotherapeutics
3B Pharmaceuticals
3D-Micromac
3DMed
3D Systems
10X Genomics
A*STAR Agency for Science
Technology and Research
A*STAR Institute of Microelectronics (IME)
A2A Pharmaceuticals
Abbvie
AbCellera
ABL Bio
Abpro
Academy of Military Medical Sciences (China)
Accellix
Accord Healthcare
AccuGenomics
ACEA Biosciences
AC Immune
Acoustic MedSystems
Adaptimmune
Aduro BioTech
Advaxis
Adventus Ventures
Aerolase
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2020-2031)
2.1.2 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics by Country/Region (2020, 2024 & 2031)
2.2 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Segment by Type
2.2.1 Asset purchase
2.2.2 Assignment
2.2.3 Co-development
2.2.4 Co-market
2.2.5 Co-promotion
2.2.6 Collaborative R&D
2.2.7 Contract service
2.2.8 CRADA
2.2.9 Cross-licensing
2.3 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type
2.3.1 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Market Share by Type (2020-2025)
2.4 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Segment by Application
2.4.1 Industry sector
2.4.2 Therapy areas
2.4.3 Technology type
2.4.4 Deal components
2.4.5 Financial terms
2.4.6 Stage of development
2.4.7 Others
2.5 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application
2.5.1 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Market Share by Application (2020-2025)
3 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Player
3.1 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Market Share by Player
3.1.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue by Player (2020-2025)
3.1.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Market Share by Player (2020-2025)
3.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics by Region
4.1 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Region (2020-2025)
4.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Annual Revenue by Country/Region (2020-2025)
4.3 Americas Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Growth (2020-2025)
4.4 APAC Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Growth (2020-2025)
4.5 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Growth (2020-2025)
4.6 Middle East & Africa Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Growth (2020-2025)
5 Americas
5.1 Americas Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2020-2025)
5.2 Americas Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2020-2025)
5.3 Americas Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Region (2020-2025)
6.2 APAC Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2020-2025)
6.3 APAC Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2020-2025)
7.2 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2020-2025)
7.3 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics by Region (2020-2025)
8.2 Middle East & Africa Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2020-2025)
8.3 Middle East & Africa Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Forecast
10.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecast by Region (2026-2031)
10.1.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecast by Region (2026-2031)
10.1.2 Americas Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecast
10.1.3 APAC Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecast
10.1.4 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecast
10.1.5 Middle East & Africa Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecast
10.2 Americas Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecast by Country (2026-2031)
10.2.1 United States Market Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecast
10.2.2 Canada Market Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecast
10.2.3 Mexico Market Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecast
10.2.4 Brazil Market Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecast
10.3 APAC Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecast by Region (2026-2031)
10.3.1 China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Forecast
10.3.2 Japan Market Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecast
10.3.3 Korea Market Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecast
10.3.4 Southeast Asia Market Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecast
10.3.5 India Market Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecast
10.3.6 Australia Market Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecast
10.4 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecast by Country (2026-2031)
10.4.1 Germany Market Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecast
10.4.2 France Market Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecast
10.4.3 UK Market Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecast
10.4.4 Italy Market Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecast
10.4.5 Russia Market Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecast
10.5 Middle East & Africa Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecast by Region (2026-2031)
10.5.1 Egypt Market Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecast
10.5.2 South Africa Market Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecast
10.5.3 Israel Market Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecast
10.5.4 Turkey Market Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecast
10.6 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecast by Type (2026-2031)
10.7 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecast by Application (2026-2031)
10.7.1 GCC Countries Market Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecast
11 Key Players Analysis
11.1 1ST Biotherapeutics
11.1.1 1ST Biotherapeutics Company Information
11.1.2 1ST Biotherapeutics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offered
11.1.3 1ST Biotherapeutics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
11.1.4 1ST Biotherapeutics Main Business Overview
11.1.5 1ST Biotherapeutics Latest Developments
11.2 3B Pharmaceuticals
11.2.1 3B Pharmaceuticals Company Information
11.2.2 3B Pharmaceuticals Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offered
11.2.3 3B Pharmaceuticals Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
11.2.4 3B Pharmaceuticals Main Business Overview
11.2.5 3B Pharmaceuticals Latest Developments
11.3 3D-Micromac
11.3.1 3D-Micromac Company Information
11.3.2 3D-Micromac Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offered
11.3.3 3D-Micromac Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
11.3.4 3D-Micromac Main Business Overview
11.3.5 3D-Micromac Latest Developments
11.4 3DMed
11.4.1 3DMed Company Information
11.4.2 3DMed Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offered
11.4.3 3DMed Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
11.4.4 3DMed Main Business Overview
11.4.5 3DMed Latest Developments
11.5 3D Systems
11.5.1 3D Systems Company Information
11.5.2 3D Systems Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offered
11.5.3 3D Systems Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
11.5.4 3D Systems Main Business Overview
11.5.5 3D Systems Latest Developments
11.6 10X Genomics
11.6.1 10X Genomics Company Information
11.6.2 10X Genomics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offered
11.6.3 10X Genomics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
11.6.4 10X Genomics Main Business Overview
11.6.5 10X Genomics Latest Developments
11.7 A*STAR Agency for Science
11.7.1 A*STAR Agency for Science Company Information
11.7.2 A*STAR Agency for Science Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offered
11.7.3 A*STAR Agency for Science Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
11.7.4 A*STAR Agency for Science Main Business Overview
11.7.5 A*STAR Agency for Science Latest Developments
11.8 Technology and Research
11.8.1 Technology and Research Company Information
11.8.2 Technology and Research Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offered
11.8.3 Technology and Research Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
11.8.4 Technology and Research Main Business Overview
11.8.5 Technology and Research Latest Developments
11.9 A*STAR Institute of Microelectronics (IME)
11.9.1 A*STAR Institute of Microelectronics (IME) Company Information
11.9.2 A*STAR Institute of Microelectronics (IME) Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offered
11.9.3 A*STAR Institute of Microelectronics (IME) Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
11.9.4 A*STAR Institute of Microelectronics (IME) Main Business Overview
11.9.5 A*STAR Institute of Microelectronics (IME) Latest Developments
11.10 A2A Pharmaceuticals
11.10.1 A2A Pharmaceuticals Company Information
11.10.2 A2A Pharmaceuticals Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offered
11.10.3 A2A Pharmaceuticals Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
11.10.4 A2A Pharmaceuticals Main Business Overview
11.10.5 A2A Pharmaceuticals Latest Developments
11.11 Abbvie
11.11.1 Abbvie Company Information
11.11.2 Abbvie Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offered
11.11.3 Abbvie Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
11.11.4 Abbvie Main Business Overview
11.11.5 Abbvie Latest Developments
11.12 AbCellera
11.12.1 AbCellera Company Information
11.12.2 AbCellera Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offered
11.12.3 AbCellera Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
11.12.4 AbCellera Main Business Overview
11.12.5 AbCellera Latest Developments
11.13 ABL Bio
11.13.1 ABL Bio Company Information
11.13.2 ABL Bio Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offered
11.13.3 ABL Bio Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
11.13.4 ABL Bio Main Business Overview
11.13.5 ABL Bio Latest Developments
11.14 Abpro
11.14.1 Abpro Company Information
11.14.2 Abpro Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offered
11.14.3 Abpro Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
11.14.4 Abpro Main Business Overview
11.14.5 Abpro Latest Developments
11.15 Academy of Military Medical Sciences (China)
11.15.1 Academy of Military Medical Sciences (China) Company Information
11.15.2 Academy of Military Medical Sciences (China) Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offered
11.15.3 Academy of Military Medical Sciences (China) Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
11.15.4 Academy of Military Medical Sciences (China) Main Business Overview
11.15.5 Academy of Military Medical Sciences (China) Latest Developments
11.16 Accellix
11.16.1 Accellix Company Information
11.16.2 Accellix Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offered
11.16.3 Accellix Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
11.16.4 Accellix Main Business Overview
11.16.5 Accellix Latest Developments
11.17 Accord Healthcare
11.17.1 Accord Healthcare Company Information
11.17.2 Accord Healthcare Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offered
11.17.3 Accord Healthcare Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
11.17.4 Accord Healthcare Main Business Overview
11.17.5 Accord Healthcare Latest Developments
11.18 AccuGenomics
11.18.1 AccuGenomics Company Information
11.18.2 AccuGenomics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offered
11.18.3 AccuGenomics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
11.18.4 AccuGenomics Main Business Overview
11.18.5 AccuGenomics Latest Developments
11.19 ACEA Biosciences
11.19.1 ACEA Biosciences Company Information
11.19.2 ACEA Biosciences Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offered
11.19.3 ACEA Biosciences Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
11.19.4 ACEA Biosciences Main Business Overview
11.19.5 ACEA Biosciences Latest Developments
11.20 AC Immune
11.20.1 AC Immune Company Information
11.20.2 AC Immune Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offered
11.20.3 AC Immune Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
11.20.4 AC Immune Main Business Overview
11.20.5 AC Immune Latest Developments
11.21 Acoustic MedSystems
11.21.1 Acoustic MedSystems Company Information
11.21.2 Acoustic MedSystems Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offered
11.21.3 Acoustic MedSystems Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
11.21.4 Acoustic MedSystems Main Business Overview
11.21.5 Acoustic MedSystems Latest Developments
11.22 Adaptimmune
11.22.1 Adaptimmune Company Information
11.22.2 Adaptimmune Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offered
11.22.3 Adaptimmune Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
11.22.4 Adaptimmune Main Business Overview
11.22.5 Adaptimmune Latest Developments
11.23 Aduro BioTech
11.23.1 Aduro BioTech Company Information
11.23.2 Aduro BioTech Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offered
11.23.3 Aduro BioTech Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
11.23.4 Aduro BioTech Main Business Overview
11.23.5 Aduro BioTech Latest Developments
11.24 Advaxis
11.24.1 Advaxis Company Information
11.24.2 Advaxis Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offered
11.24.3 Advaxis Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
11.24.4 Advaxis Main Business Overview
11.24.5 Advaxis Latest Developments
11.25 Adventus Ventures
11.25.1 Adventus Ventures Company Information
11.25.2 Adventus Ventures Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offered
11.25.3 Adventus Ventures Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
11.25.4 Adventus Ventures Main Business Overview
11.25.5 Adventus Ventures Latest Developments
11.26 Aerolase
11.26.1 Aerolase Company Information
11.26.2 Aerolase Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product Offered
11.26.3 Aerolase Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
11.26.4 Aerolase Main Business Overview
11.26.5 Aerolase Latest Developments
12 Research Findings and Conclusion
听
听
*If Applicable.
